Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20686120
Hoang B, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-8 20686120
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase slight increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 no effect upon treatment-induced increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 augment treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase
rapamycin no change compared to control
RICTOR (human) no change compared to control shRNA no change
IL-6 increase in OPM2 and MM1S MM cells, not in U266 and 8226 MM cells
PTEN (human) decrease
NRas (human) increase
KRas (human) decrease
PP242 decrease MM patient cells

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

S2481-p - mTOR (human)
Modsite: tVPEsIHsFIGDGLV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase
PP242 decrease MM patient cells

S330-p - NDRG1 (human)
Modsite: LMRsRtAsGssVtsL SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): S330‑p, NDRG1 iso2 (human): S264‑p, NDRG1 iso3 (human): S249‑p, NDRG1 (mouse): S330‑p, NDRG1 (rat): S330‑p, NDRG1 (cow): S330‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 no effect upon treatment-induced increase
RICTOR (human) increase shRNA decreases

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  multiple myeloma
Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (plasma cell), RPMI-8226 (plasma cell), U266 (plasma cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 inhibit treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase